Pharma BD Deal Intelligence
Roche agreed to pay $725M upfront and up to $1B in milestones for Seragon, betting next-gen oral SERDs led by ARN-810 could rewrite the standard of care in ER+…
Roche scrapped RG6046, the centerpiece of its 2014 Seragon acquisition, but kept investing in follow-on SERDs that would later become giredestrant.
FDA accepted the NDA for giredestrant in ESR1-mutated, ER+ advanced breast cancer — a regulatory milestone tracing back to the 2014 Seragon acquisition.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Roche/Genentech acquired private San Diego biotech Seragon Pharmaceuticals (spun out of Aragon/J&J) for $725M cash plus up to $1B in milestones, gaining a portfolio of oral SERDs led by ARN-810 for ER+ breast cancer. The deal seeded what later became Roche's giredestrant program.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Seragon Pharmaceuticals, Inc. (this deal) | 2014 | $1.7B | 53 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2014 deals · Roche Holding AG deals · Oncology deals